Dual drug loaded nanoliposomal chemotherapy: A promising strategy for treatment of head and neck squamous cell carcinoma

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 99, Issue , 2016, Pages 73-83

  Mohan, Aarti ^a   Narayanan, Shridhar ^b   Balasubramanian, Gopalan ^b   Sethuraman, Swaminathan ^a   Krishnan, Uma Maheswari ^a  

^a SASTRA UNIVERSITY   (India)

^b Orchid Chemicals and Pharmaceuticals Ltd   (India)

Author keywords

Apoptosis; Doxorubicin hydrochloride; Liposomes; Oral cancer; Resveratrol

Indexed keywords

CYCLIN A2; CYCLIN B1; CYCLIN D1; DOXORUBICIN; LIPOSOME; NANOCARRIER; PHOSPHATIDYLCHOLINE; RESVERATROL; ANTINEOPLASTIC AGENT; NANOPARTICLE; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG UPTAKE; ENDOCYTOSIS; GLASS TRANSITION TEMPERATURE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIPOSOMAL DELIVERY; MOUTH SQUAMOUS CELL CARCINOMA; NANOENCAPSULATION; NANOPHARMACEUTICS; ORAL CANCER CELL LINE; PHAGOCYTOSIS; PINOCYTOSIS; PROTEIN EXPRESSION; SURFACE CHARGE; THERMOSTABILITY; ZETA POTENTIAL; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEAD AND NECK NEOPLASMS; MEDICINAL CHEMISTRY; PROCEDURES; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HEAD AND NECK NEOPLASMS; HUMANS; LIPOSOMES; NANOPARTICLES; STILBENES;

EID: 84950120055     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.11.017     Document Type: Article

References (63)

1. P. Parikh, V. Patil, J.P. Agarwal, and et al. Guidelines for treatment of recurrent or metastatic head and neck cancer Indian J. Cancer 51 2014 89 94
2. T.M. Allen, and P.R. Cullis Liposomal drug delivery systems: from concept to clinical applications Adv. Drug Deliv. Rev. 65 2013 36 48
3. B. Kneidl, M. Peller, G. Winter, and et al. Thermosensitive liposomal drug delivery systems: state of the art review Int. J. Nanomed. 9 2014 4387 4398
4. J. Wolfram, M. Zhu, Y. Yang, and et al. Safety of nanoparticles in medicine Curr. Drug Targets 16 2015 1671 1681
5. Z. Wu, B.E.C. Liu, J. Liu, and et al. Resveratrol inhibits the proliferation of human melanoma cells by inducing G1/S cell cycle arrest and apoptosis Mol. Med. Rep. 11 2015 400 404
6. C.K. Singh, J. George, and N. Ahmad Resveratrol-based combinatorial strategies for cancer management Ann. N. Y. Acad. Sci. 1290 2013 113 121
7. A. Movahed, L. Yu, S.J. Thandapilly, and et al. Resveratrol protects adult cardiomyocytes against oxidative stress mediated cell injury Arch. Biochem. Biophys. 527 2012 74 80
8. S. Bo, G. Ciccone, A. Castiglione, and et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial Curr. Med. Chem. 20 2013 1323 1331
9. V. Kumar, V.K. Tripathi, A.K. Singh, and et al. Trans-resveratrol restores the damages induced by organophosphate pesticide-monocrotophos in neuronal cells Toxicol. Int. 20 2013 48 55
10. E. Scott, W.P. Steward, A.J. Gescher, and et al. Resveratrol in human cancer chemoprevention - choosing the 'right' dose Mol. Nutr. Food Res. 56 2012 7 13
11. C.H. Cottart, V. Nivet-Antoine, and J.L. Beaudeux Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans Mol. Nutr. Food Res. 58 2014 7 21
12. K. Shigeyasu, S. Kagawa, F. Uno, and et al. Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination Cancer Chemother. Pharmacol. 71 2013 937 943
13. J.H. Lorch, O. Goloubeva, R.I. Haddad, and et al. TAX 324 Study Group. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial Lancet Oncol. 12 2011 153 159
14. X. Li, F. Zhu, J. Jiang, and et al. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells Cancer Lett. 357 2015 219 230
15. S.Z. Li, K. Li, J.H. Zhang, and et al. The effect of quercetin on doxorubicin cytotoxicity in human breast cancer cells Anticancer Agents Med. Chem. 13 2013 352 355
16. J.Y. Chen, R.Y. Hu, and H.C. Chou Quercetin-induced cardioprotection against doxorubicin cytotoxicity J. Biomed. Sci. 20 2013 95
17. T.H. Kim, Y.J.A. Shin, J. Won, and et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin Biochim. Biophys. Acta 1840 2014 615 625
18. J. Díaz-Chávez, M.A. Fonseca-Sánchez, E. Arechaga-Ocampo, and et al. Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy PLoS ONE 8 2013 e64378
19. A.M.M. Osman, H.M. Bayoumi, S.E. Al-Harthi, and et al. Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line Cancer Cell Int. 12 2012 47
20. X. Huang, X.N. Xu, J. Chen, and et al. Resveratrol reverses multidrug resistance in human breast cancer doxorubicin-resistant cells Exp. Ther. Med. 7 2014 1611 1616
21. X. Xu, K. Chen, S. Kobayashi, and et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy J. Pharmacol. Exp. Ther. 341 2012 183 195
22. D. Pramanik, N.R. Campbell, S. Das, and et al. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy Oncotarget 3 2012 640 650
23. B.L. Wang, Y.M. Shen, Q.W. Zhang, and et al. Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer Int. J. Nanomed. 8 2013 3521 3531
24. R. Mulherkar, A.P. Goud, A.S. Wagle, and et al. Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract Cancer Lett. 118 1997 115 121
25. M. Gohel, and S.A. Nagori Fabrication and evaluation of captopril modified-release oral formulation Pharm. Dev. Technol. 14 2009 679 686
26. A. Gabizon, R. Shiota, and D. Papahadjopoulos Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times J. Natl. Cancer Inst. 81 1989 1484 1488
27. W. Voigt Suphorhodamine assay and chemosensitivity R.D. Blumenthal, Methods Molecular Medicine 2005 Humana Press New Jersey 39 48
28. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and et al. Protein measurement with Folin phenol reagent J. Biol. Chem. 193 1951 265 275
29. M.H. Gaber, M.M. Ghannam, S.A. Ali, and et al. Interaction of Doxorubicin with phospholipid monolayer and liposomes Biophys. Chem. 70 1998 223 229
30. S. Selvaraj, A. Mohan, S. Narayanan, and et al. Dose-dependent interaction of trans-resveratrol with biomembranes: effects on antioxidant property J. Med. Chem. 56 2013 970 981
31. A. Mohan, S. Narayanan, S. Sethuraman, and et al. Novel resveratrol and 5-fluorouracil coencapsulated in PEGylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma Biomed. Res. Int. 2014 2014 424239
32. K. Maruyama Intracellular targeting of liposomal drugs to solid tumors based on EPR effects Adv. Drug Deliv. Rev. 63 2011 161 169
33. L.M. Immordino, F. Dosio, and L. Cattel Stealth liposomes: a review of basic science, rationale and clinical applications, existing and potential Int. J. Nanomed. 1 2006 297 315
34. I. Mac Lachlan Liposomal formulations for nucleic acid delivery S.T. Crooke, Antisense Drug Technology: Principles, Strategies and Applications 2008 CRC Press Florida 253
35. M.H. Chiu, and E.J. Prenner Differential scanning calorimetry: an invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions J. Pharm. Bioallied Sci. 3 2011 39 59
36. G.S. Karczmar, and T.R. Tritton The interaction of adriamycin with small unilamellar vesicle liposomes. A fluorescence study Biochim. Biophys. Acta 557 1979 306 319
37. T.R. Tritton, S.A. Murphree, and A.C. Sartorelli Adriamycin: a proposal on the specificity of drug action Biochem. Biophys. Res. Commun. 84 1978 802 808
38. N. Henry-Toulme, B. Stefanska, E. Borowski, and et al. Structural basis for the binding of antitumor anthracycline antibiotics to model membranes: circular dichroism studies Mol. Pharmacol. 33 1988 574 579
39. L. Dupou-Cézanne, A.M. Sautereau, and J.F. Tocanne Localization of adriamycin in model and natural membranes. Influence of lipid molecular packing Eur. J. Biochem. 181 1989 695 702
40. Y. Fu, and W.J. Kao Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems Expert Opin. Drug Deliv. 7 2010 429 444
41. L. Zhao, L. Zhu, F. Liu, and et al. PH triggered injectable amphiphilic hydrogel containing doxorubicin and paclitaxel Int. J. Pharm. 410 2011 83 91
42. K. Na, E.S. Lee, and Y.H. Bae Self-organized nanogels responding to tumor extracellular pH: pH-dependent drug release and in vitro cytotoxicity against MCF-7 cells Bioconjug. Chem. 18 2007 1568 1574
43. L.N. Ramana, S. Sethuraman, U. Ranga, and et al. Development of a liposomal nanodelivery system for nevirapine J. Biomed. Sci. 17 2010 57
44. N. Oh, and J.H. Park Endocytosis and exocytosis of nanoparticles in mammalian cells Int. J. Nanomed. 9 2014 51 63
45. J. Rejman, V. Oberle, I.S. Zuhorn, and et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis Biochem. J. 377 2004 159 169
46. L. Treuel, X. Jiang, and G.U. Nienhaus New views on cellular uptake and trafficking of manufactured nanoparticles J. R. Soc. Interface 10 2013 20120939
47. T.C. Chou Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
48. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
49. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
50. T.C. Chou Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro Contrib. Gynecol. Obstet. 19 1994 91 107
51. M. Fu, C. Wang, Z. Li, and et al. Cyclin D1: normal and abnormal functions Endocrinology 145 2004 5439 5447
52. M. Stamatakos, V. Palla, I. Karaiskos, and et al. Cell cyclins: triggering elements of cancer or not World J. Surg. Oncol. 8 2010 111
53. V. Kothari, and R. Mulherkar Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma Anticancer Res. 32 2012 121 128
54. P. Parekh, L. Motiwale, N. Naik, and et al. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells Exp. Toxicol. Pathol. 63 2011 167 173
55. G. Gatouillat, E. Balasse, D. Joseph-Pietras, and et al. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma J. Cell. Biochem. 110 2010 893 902
56. P.F. Rezaei, S. Fouladdel, S. Hassani, and et al. Induction of apoptosis and cell cycle arrest by pericarp polyphenol-rich extract of Baneh in human colon carcinoma HT29 cells Food Chem. Toxicol. 50 2012 1054 1059
57. A. Zuryn, A. Grzanka, A. Stepien, and et al. Expression of cyclin A in human leukemia cell line HL-60 following treatment with doxorubicin and etoposide: the potential involvement of cyclin A in apoptosis Oncol. Rep. 17 2007 1013 1019
58. X. Wang, Y. Song, J. Ren, and et al. Knocking-down cyclin A(2) by siRNA suppresses apoptosis and switches differentiation pathways in K562 cells upon administration with doxorubicin PLoS ONE 4 2009 e6665
59. T. Abbas, and A. Dutta P21 in cancer: intricate networks and multiple activities Nat. Rev. Cancer 9 2009 400 414
60. Y.H. Jin, K.J. Yoo, Y.H. Lee, and et al. Caspase 3-mediated cleavage of p21WAF1/CIP1 associated with the cyclin A-cyclin-dependent kinase 2 complex is a prerequisite for apoptosis in SK-HEP-1 cells J. Biol. Chem. 275 2000 30256 30263
61. A.B. Parrish, and S. Freel CD Kornbluth Cellular mechanisms controlling caspase activation and function Cold Spring Harb. Perspect. Biol. 5 2013 pii: a008672
62. C. Soldani, M.C. Lazzè, M.G. Bottone, and et al. Poly (ADP-ribose) polymerase cleavage during apoptosis: when and where? Exp. Cell Res. 269 2001 193 201
63. C.A. Casiano, R.L. Ochs, and E.M. Tan Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes Cell Death Differ. 5 1998 183 190